FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3018924880> ?p ?o ?g. }

• W3018924880 endingPage "1861" @default.
• W3018924880 startingPage "1851" @default.
• W3018924880 abstract "Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide has long been a subject of debate. We performed a phase II randomized trial investigating whether extending adjuvant temozolomide for more than 6 cycles improved outcome.Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after 6 cycles of adjuvant temozolomide were centrally randomized to stop (control arm) or continue (experimental arm) temozolomide up to a total of 12 cycles at the same doses they were receiving in cycle 6. Patients were stratified by MGMT methylation and measurable disease. The primary endpoint was differences in 6-month progression-free survival (PFS). Secondary endpoints were PFS, overall survival (OS), and safety (Clinicaltrials.gov NCT02209948).From August 2014 to November 2018, 166 patients were screened, 7 of whom were ineligible. Seventy-nine patients were included in the stop arm and 80 in the experimental arm. All patients were included in the analyses of outcomes and of safety. There were no differences in 6-month PFS (control 55.7%; experimental 61.3%), PFS, or OS between arms. MGMT methylation and absence of measurable disease were independent factors of better outcome. Patients in the experimental arm had more lymphopenia (P < 0.001), thrombocytopenia (P < 0.001), and nausea and vomiting (P = 0.001).Continuing temozolomide after 6 adjuvant cycles is associated with greater toxicity but confers no additional benefit in 6-month PFS.1. Extending adjuvant temozolomide to 12 cycles did not improve 6-month PFS.2. Extending adjuvant temozolomide did not improve PFS or OS in any patient subset.3. Extending adjuvant temozolomide was linked to increased toxicities." @default.
• W3018924880 created "2020-05-01" @default.
• W3018924880 creator A5005526813 @default.
• W3018924880 creator A5008091556 @default.
• W3018924880 creator A5014016108 @default.
• W3018924880 creator A5024258526 @default.
• W3018924880 creator A5028793195 @default.
• W3018924880 creator A5029272790 @default.
• W3018924880 creator A5036830524 @default.
• W3018924880 creator A5037165485 @default.
• W3018924880 creator A5037959756 @default.
• W3018924880 creator A5039768299 @default.
• W3018924880 creator A5040327732 @default.
• W3018924880 creator A5047678330 @default.
• W3018924880 creator A5049143229 @default.
• W3018924880 creator A5051150341 @default.
• W3018924880 creator A5052470503 @default.
• W3018924880 creator A5057408102 @default.
• W3018924880 creator A5057499890 @default.
• W3018924880 creator A5057504926 @default.
• W3018924880 creator A5060914752 @default.
• W3018924880 creator A5065204272 @default.
• W3018924880 creator A5068271097 @default.
• W3018924880 creator A5071763441 @default.
• W3018924880 creator A5073703908 @default.
• W3018924880 creator A5074054602 @default.
• W3018924880 creator A5080151764 @default.
• W3018924880 creator A5080323920 @default.
• W3018924880 creator A5081635082 @default.
• W3018924880 creator A5082835290 @default.
• W3018924880 creator A5083469127 @default.
• W3018924880 creator A5083953636 @default.
• W3018924880 date "2020-04-24" @default.
• W3018924880 modified "2023-10-18" @default.
• W3018924880 title "A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)" @default.
• W3018924880 cites W1808226550 @default.
• W3018924880 cites W1882634342 @default.
• W3018924880 cites W1971344938 @default.
• W3018924880 cites W1975104842 @default.
• W3018924880 cites W1988768248 @default.
• W3018924880 cites W2026656096 @default.
• W3018924880 cites W2094581885 @default.
• W3018924880 cites W2096287682 @default.
• W3018924880 cites W2096731080 @default.
• W3018924880 cites W2097478662 @default.
• W3018924880 cites W2105100844 @default.
• W3018924880 cites W2113729674 @default.
• W3018924880 cites W2126817554 @default.
• W3018924880 cites W2135947790 @default.
• W3018924880 cites W2162643152 @default.
• W3018924880 cites W2164061282 @default.
• W3018924880 cites W2288156681 @default.
• W3018924880 cites W2410468716 @default.
• W3018924880 cites W2599750069 @default.
• W3018924880 cites W2600112631 @default.
• W3018924880 cites W2741824219 @default.
• W3018924880 cites W2749747068 @default.
• W3018924880 cites W2778283729 @default.
• W3018924880 cites W2902409020 @default.
• W3018924880 cites W2903914616 @default.
• W3018924880 doi "https://doi.org/10.1093/neuonc/noaa107" @default.
• W3018924880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7746946" @default.
• W3018924880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32328662" @default.
• W3018924880 hasPublicationYear "2020" @default.
• W3018924880 type Work @default.
• W3018924880 sameAs 3018924880 @default.
• W3018924880 citedByCount "58" @default.
• W3018924880 countsByYear W30189248802020 @default.
• W3018924880 countsByYear W30189248802021 @default.
• W3018924880 countsByYear W30189248802022 @default.
• W3018924880 countsByYear W30189248802023 @default.
• W3018924880 crossrefType "journal-article" @default.
• W3018924880 hasAuthorship W3018924880A5005526813 @default.
• W3018924880 hasAuthorship W3018924880A5008091556 @default.
• W3018924880 hasAuthorship W3018924880A5014016108 @default.
• W3018924880 hasAuthorship W3018924880A5024258526 @default.
• W3018924880 hasAuthorship W3018924880A5028793195 @default.
• W3018924880 hasAuthorship W3018924880A5029272790 @default.
• W3018924880 hasAuthorship W3018924880A5036830524 @default.
• W3018924880 hasAuthorship W3018924880A5037165485 @default.
• W3018924880 hasAuthorship W3018924880A5037959756 @default.
• W3018924880 hasAuthorship W3018924880A5039768299 @default.
• W3018924880 hasAuthorship W3018924880A5040327732 @default.
• W3018924880 hasAuthorship W3018924880A5047678330 @default.
• W3018924880 hasAuthorship W3018924880A5049143229 @default.
• W3018924880 hasAuthorship W3018924880A5051150341 @default.
• W3018924880 hasAuthorship W3018924880A5052470503 @default.
• W3018924880 hasAuthorship W3018924880A5057408102 @default.
• W3018924880 hasAuthorship W3018924880A5057499890 @default.
• W3018924880 hasAuthorship W3018924880A5057504926 @default.
• W3018924880 hasAuthorship W3018924880A5060914752 @default.
• W3018924880 hasAuthorship W3018924880A5065204272 @default.
• W3018924880 hasAuthorship W3018924880A5068271097 @default.
• W3018924880 hasAuthorship W3018924880A5071763441 @default.
• W3018924880 hasAuthorship W3018924880A5073703908 @default.
• W3018924880 hasAuthorship W3018924880A5074054602 @default.
• W3018924880 hasAuthorship W3018924880A5080151764 @default.
• W3018924880 hasAuthorship W3018924880A5080323920 @default.

• next